No Data
No Data
Pacific Securities: pay attention to investment opportunities in the fields of food and fodder additives, and phosphorus chemicals.
Pacific Securities research reports suggest focusing on investment opportunities in the food and fodder additive, and phosphorus chemicals sectors.
CITIC Securities: The recovery slope of the condiment industry has slowed down, and the online and industrial layout is expected to become a new increment.
With the expansion of food delivery and the popularity of pre-cooked food, part of the condiment consumption on the household end has shifted to dining and food industry channels such as pre-cooked food and cooking packages, bringing new growth to the industry. The demand for the restoration of pre-cooked food flavors has increased, and the requirements for condiment enterprises have gradually strengthened. The trend towards industrialization has become a new opportunity.
Changmao Biotech (00954.HK) received 316,000 H shares from Rui Xinsheng, worth about HK$132,200
On May 7, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on May 7, Rui Xinsheng increased its H share holdings of $Changmao Biotech (00954.HK) by $316,000 at an average price of HK$0.4183 per share on May 6, worth about HK$132,200. After increasing its holdings, Rui Xinsheng's latest shareholding was 12.236 million shares, and the good position ratio rose from 6.49% to 6.66%. This transaction involves another related party: Leng Yixin. Image source: Stock Exchange Equity Disclosure (partial table of this incident) What is equity disclosure? According to the requirements of the Hong Kong Stock Exchange, major shareholders (individuals holding 5% or more of the shares
Changmao Biotech (00954.HK) obtained 120,000 H shares from Rui Xinsheng, worth approximately HK$492,000
On April 25, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on April 25, Rui Xinsheng increased its H share holdings of $Changmao Biotech (00954.HK) by $120,000 at an average price of HK$0.41 per share on April 24, worth about HK$492,000. After increasing its holdings, Rui Xinsheng's latest shareholding was 11.92 million shares, and the good position ratio increased from 6.42% to 6.49%. This transaction involves another related party: Leng Yixin. Image source: Stock Exchange Equity Disclosure (partial table of this incident) What is equity disclosure? Major shareholders (individuals and companies holding 5% or more of the shares) as required by the Hong Kong Stock Exchange
Changmao Biotech (00954.HK) received 2.196 million H shares from Rui Xinsheng, worth approximately HK$835,600
On April 22, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on April 22, Rui Xinsheng increased its H share holdings of $Changmao Biotech (00954.HK) $2.196 million at an average price of HK$0.3805 per share on April 19, worth about HK$835,600. After increasing its holdings, Rui Xinsheng's latest shareholding was 11.8 million shares, and the good position ratio increased from 5.23% to 6.42%. This transaction involves another related party: Leng Yixin. Image source: Stock Exchange Equity Disclosure (partial table of this incident) What is equity disclosure? According to the requirements of the Hong Kong Stock Exchange, major shareholders (those holding 5% or more of the shares
CHANGMAO BIO: ANNUAL REPORT 2023
No Data